- Addition of IW-1973 to ongoing medical regimens used to treat diabetic patients with hypertension showed reductions in blood pressure, fasting plasma glucose, cholesterol and triglycerides, and improved endothelial function - -Data support advancement of IW-1973 for evaluation as a potential
- William Huyett Appointed to Chief Operating Officer - - Gina Consylman Promoted to Senior Vice President, Chief Financial Officer - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the appointment of William
- Ironwood revenue grew 31% to $87 million in 3Q 2017 over 3Q 2016 - - LINZESS ® (linaclotide) U.S. net sales increased 16% to $191 million and net profit increased 36% to $111 million in 3Q 2017 over 3Q 2016 - - Launched DUZALLO ® (lesinurad and allopurinol), a once-daily fixed-dose combination
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Credit Suisse 26 th Annual Healthcare Conference on Wednesday, November 8 th , 2017 at 10:25 a.m. Mountain Time / 12:25 p.m. Eastern Time at The Phoenician in Scottsdale,
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017 . The meeting is hosted by the American College of
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 2, 2017 . Individuals interested in participating in the call should
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a commercial biotechnology company, today announced that the company and its collaborators are presenting clinical data for linaclotide at the World Congress of Gastroenterology (WCOG) at the American College of
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that Tom Graney , chief financial officer (CFO) and senior vice president, finance and corporate strategy will leave the company, effective September 13, 2017 , to pursue another opportunity.
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017 at 1:40 p.m. ET at The Westin Boston Waterfront in Boston .
- Once-Daily DUZALLO Is the First FDA-Approved Fixed-Dose Combination Treatment That Addresses Both Causes of Hyperuricemia in Gout, Over-Production and Under-Excretion of Serum Uric Acid, In A Single Pill - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.
You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.
Delicious
Digg
Facebook
LinkedIn
Twitter
